Genotyping Services

Home - biosciences - Page 2

Genotyping Services

 

 

Genotyping Services

The Randox Genomics Services Department currently has target genotyping solutions in multiple areas. Genotyping is the process of analysing DNA to detect SNPs of interest. These SNPs are compared to reference SNPs, available from years of genetic research, to determine differences in genetic makeup.

Genotyping Advantages and Applications

Clinical Diagnostics

  • Can help determine whether specific resistance genes or genetic mutations in bacterial strains- make it insusceptible to one or more antibiotic drug.
  • Can be used to help monitor variants during pandemics, identifying when new variants become more predominant.

Clinical Research

  • Allows researchers to focus on genes, variants, and genomic regions of interest relevant to certain disease or traits of interest.
  • Enables the study of populations not supported by standard products and can be used to create personalised drugs.

Food & Agriculture

  • Identifies potential genes for improving breeding and management programs.
  • Can be used to increase yield and improve quality

Pharmacogenomics

Pharmacogenomics (PGx) is the study of how a person’s DNA effects their drug response. This is a relatively new field in science but it is expected to be the future of medicine as it focuses on personalised medicine and treating every patient individually.

Microarray Technology for PGx

At Randox we use Illumina’s Infinium Global Diversity Array with Enhanced PGx microarray to test for pharmacogenomic markers. This is the most comprehensive genotyping microarray on the market for pharmacogenomic research. The microarray features over 44,000 genome-wide PGx markers which span more than 20000 pharmacogenomic targets and gives 100% coverage of priority level A and B CPIC genes.

Genotyping Panels

  • null
    GSA + Custom content

    Over 710,000 SNPs across the human genome with additional DTC content.

  • null
    GDA + Enhanced PGx

    Over 1.8 million SNPs across the human genome enhanced with pharmacogenomic specific markers.

Laboratory Technology

Find Out More

Genotyping Workflow

Related Services

CDx & Biopharma Services


Genomics Services

 

 

Genomics Services

An End-to-End Genomics Solution

Randox Genomics Services department is fitted with specialised, fully equipped, state of the art testing facilities, designed and set up to fulfil a unique range of end-to-end sequencing solutions inclusive of in-house bioinformaticians and data analysts.

Why Randox?

Randox Laboratories is a global market leader within the in vitro diagnostics industry. Utilising a multitude of platforms, our sequencing and genotyping facility is suited to a wide range of areas of genome sequencing.

Our team of genetic scientists and bioinformaticians provide customisable sequencing and genotyping services for research, development, validation and running of different genomic tests to generate high quality data in line with modern healthcare and future disease insights.

  • null

    A dedicated team of genetic scientists including automation specialists, enabling adaption to testing throughputs changes from call small projects to large scale testing.

  • null

    Huge capacity for storage and accessioning of multiple sample types with fast turnaround times.

  • null

    Specific customised project planning and validation of services, tailored to the needs of each Randox customer.

  • null

    Multiple options for variable throughput from low throughput instruments, to the largest sequencer on the market with targeted solutions in multiple areas.

  • null
    Targeted genotyping solutions in multiple areas

Our Services

Genotyping

OLINK®

Related Services

CDx & Biopharma Services


OLINK

OLINK® | Comprehensive Biomarker Discovery

 

Let Experts at Randox Run Your Samples

As one of the UK’s first commercial partners of Olink® Proximity Extension Assay (PEA) technology, Randox offer scientists involved in drug development, clinical, or basic life science research, the service they need to run large-scale discovery proteomics.

Considered as a next-gen proteomics platform, Olink® technology is widely recognised and extensively cited in various research fields for protein profiling and biomarker development.

As an Olink® Certified Service Provider, Randox are experts in generating high-quality data using all Olink® proteomic platforms.

Supported Olink® Platforms

Randox Service portfolio includes high throughput protein analysis using cutting-edge Olink® technology. We are experts in generating high-quality data using all Olink®  proteomic platforms. Allow the Randox team to assist you in discovering how this versatile assay can advance your research by getting in touch or visiting the Olink® Website.

null

Olink® Explore HT

Proteins (per panel): 5,400 +

Sample: 2 µL

Multiplex Panels: 1

Quantification: Relative

null

Olink® Explore 384

Proteins (per panel) ~3000

Sample: 1 µL

Multiplex Panels: 8

Quantification: Relative

null

Olink® Target 96

Proteins (per panel) ~ 1100

Sample: 1 µL

Multiplex Panels: 15

Quantification: Relative

null

Olink® Target 48 Cytokine

Proteins (per panel): 45

Sample: 1 µL

Multiplex Panels: 1

Quantification: Relative

null

Olink® Flex

Proteins (per panel) ~200

Sample: 1 µL

Multiplex Panels: Mix & Match

Quantification: Relative or absolute

null

Olink® Focus

Proteins (per panel) 5400+

Sample: 1 µL

Multiplex Panels: Custom

Quantification: Relative or absolute

Features and Benefits

  • null
    Covers all major biological pathways with ~5400 + validated protein assays
  • null
    High sample throughput for large scale proteomic studies and research
  • null
    Minimal sample volume with just 60uL for the complete library
  • null
    Exceptional specificity in comparison to mass spec utilising PEA technology
  • null
    Compatible with a wide variety of sample types

Olink® Workflow

Randox Successfully Completed Olink® Concordance Testing

Randox successfully completed the Explore Concordance challenge as beta testers of the Concordance program, certifying the ability to operate the PEA with the same level of competency as the Olink® Analysis Service.

Randox Summary Report Acceptance Criteria Result
QC Warnings0%Max 16% allowed Passed the QC warning criteria
Detectability97.2%Min 85% allowed Passed the detectability criteria
Intra CV9%Max 15% allowedPassed the CV criteria
Median correlation coefficient (r)0.98Min 0.9 allowedPassed the correlation criteria.
Coefficient of determination (R2)0.96Min 0.9 allowedPassed the correlation criteria.
Overall, Randox passed all QC criteria, successfully passing the Olink Concordance Test on Explore 3072.
Download Full Report

Related Services

CDx & Biopharma Services


Vivalytic | Monkeypox (MPXV)

Vivalytic | MPXV

 

Detection of Monkeypox Virus and non-variola Orthopoxvirus species.

*Research Use Only

RT-PCR detection of Monkeypox Virus and non-variola Orthopoxvirus species.

  • null
    Quick turnaround time of 45 minutes, beneficial for both the patient and for the containment of Monkeypox
  • null
    Convenient 4 step process from sample entry to results. Suitable for use in laboratory and non-laboratory settings
  • null
    Two target approach: Detection of MPXV and Orthopoxvirus species (including MPXV)

Clinical Significance

Vivalytic Monkeypox virus (MPXV) is a rapid and user-friendly test designed to aid the global response against Monkeypox. Monkeypox is a zoonotic virus belonging to the Orthopoxvirus subset genus within the Poxviridae family. It spreads between species through animal bites and the transfer of bodily fluids. Human-to-human transmission can occur through contact with infected lesions, inhalation of respiratory droplets, and indirect exposure to contaminated objects. Sexual contact is recognised as a significant mode of transmission during outbreaks of infection.

The Vivalytic MPXV Panel is specifically developed to detect the presence of the Monkeypox virus and non-variola orthopoxvirus species. With a remarkable time-to-result of just 45 minutes, this cutting-edge test offers swift and accurate screening of these viral pathogens, improving outbreak containment and prevention.

Features

Sample Type: Swab

Sample Volume: 300μL

Detection Method: Real-Time PCR

Time to result: 45 minutes

Detectable Pathogens
Monkeypox Virus (Clade I, Clase II)Non-variola Orthopoxvirus species (Coqpox Virus, Ectromelia Virus, Monkeypox Cirus, Taterapox Virus, Vaccinia Virus)

“AWARD-WINNING DESIGN DELIVERS
AN UNCOMPLICATED USER EXPERIENCE”

Vivalytic Workflow

Intuitive engineering of Vivalytic ensures the analyser is user friendly. The process of patient sample to result comprises a very simple 4 step workflow.

To begin the test, the user scans or enters sample information. The cartridge code is then scanned into the embedded Vivalytic software. The user then adds sample into the dedicated cartridge slot, closes the lid and inserts the cartridge into the Vivalytic.

The touchscreen display will countdown the time remaining to test completion. Results will be displayed on the screen. Multiple Vivalytics can be wirelessly connected allowing the user to control multiple tests at one time all reporting to a master Vivalytic platform.

Download Vivalytic Brochure

Want to know more?

Contact us or visit our COVID-19 Monitoring & Management page

Related Products

Viral Respiratory Infection Array

SARS-CoV-2 Pooling Test

Vivalytic

Vivalytic Test Menu


Randox Biosciences Resource Hub

Resource Hub | Biosciences

  • Brochures
  • Clinical Studies Group Publications
  • Flyers
  • Videos

Biosciences overview

Immunology

Molecular Testing

CDx & Biopharma Services

Cardiovascular & Metabolic

Acute Kidney Injury

2019.Stratifying risk of acute kidney injury in pre and post cardiac surgery patients using a novel biomarker-based algorithm and clinical risk score

Stratifying risk of acute kidney injury in pre and post cardiac surgery patients using a novel biomarker-based algorithm and clinical risk score - 2019

2021.Blood and urinary cytokine balance and renal outcomes at cardiac surgery

Blood and urinary cytokine balance and renal outcomes at cardiac surgery - 2021

2020.Acute kidney injury risk in orthopaedic trauma patients pre and post surgery using a biomarker algorithm and clinical risk score

Acute kidney injury risk in orthopaedic trauma patients pre- and post-surgery using a biomarker algorithm and clinical risk score - 2020

2020.Stratifying-Risk-of-Acute-Kidney-Injury-in-Pre-and-Post-Cardiac-Surgery-Patients-Using-a-Novel-Biomarker-Based-Algorithm-and-Clinical-Risk-Score

Stratifying Risk of Acute Kidney Injury in Pre- and Post-Cardiac Surgery Patients Using a Novel Biomarker Based Algorithm and Clinical Risk Score - 2020

ARID

2022.Plasma Soluble Tumor Necrosis Factor Receptor Concentrations and Clinical Events After Hospitalization- Findings From the ASSESS-AKI and ARID Studies

Plasma Soluble Tumor Necrosis Factor Receptor Concentrations and Clinical Events After Hospitalization- Findings From the ASSESS-AKI and ARID Studies - 2022

Diabetic Nephropathy

_2021_Harkin_On_tissue_chemical_derivatization_in_mass_spectrometry_imaging

On tissue chemical derivatization in mass spectrometry imaging - 2021

2022.Biomarkers for Detecting Kidney Dysfunction in Type-2 Diabetics and Diabetic Nephropathy Subjects A Case-Control Study to Identify Potential Biomar

Biomarkers for Detecting Kidney Dysfunction in Type-2 Diabetics and Diabetic Nephropathy Subjects A Case-Control Study to Identify Potential Biomarkers - 2022

2023.Analysis of reactive aldehydes in urine and plasma of type-2 diabetes mellitus patients through liquid chromatography-mass spectrometry Reactive al

Analysis of reactive aldehydes in urine and plasma of type-2 diabetes mellitus patients through liquid chromatography-mass spectrometry: Reactive aldehydes as potential markers of diabetic nephropathy - 2023

HABIO

2019.op68-value-engineered-translation-an-example-for-bladder-cancer-diagnosis

op68 value engineered translation an example for bladder cancer diagnosis - 2019

2020.Thrombomodulin Expression in Bladder Cancer Tissue and Its Association with Prognosis and Patient Survival

Thrombomodulin Expression in Bladder Cancer Tissue and Its Association with Prognosis and Patient Survival - 2020

2022.Biomarkers to assess the risk of bladder cancer in patients presenting with haematuria are gender-specific

Biomarkers to assess the risk of bladder cancer in patients presenting with haematuria are gender-specific - 2022

2024.Stratifying risk of disease in haematuria patients using machine learning techniques to improve diagnostics

Stratifying risk of disease in haematuria patients using machine learning techniques to improve diagnostics - 2024

HABIO Diabetes

2020.Stratifying-Risk-of-Acute-Kidney-Injury-in-Pre-and-Post-Cardiac-Surgery-Patients-Using-a-Novel-Biomarker-Based-Algorithm-and-Clinical-Risk-Score

Clinical features and predictive biomarkers for bladder cancer in patients with type 2 diabetes presenting with haematuria - 2022

MACE

2022.A novel algorithm for cardiovascular screening using conjunctival microcirculatory parameters and blood biomarkers.pdf

A novel algorithm for cardiovascular screening using conjunctival microcirculatory parameters and blood biomarkers - 2022

MAST4Health

2018. The 9th Santorini Conference- Systems Medicine

The 9th Santorini Conference: Systems Medicine, Personalised Health and Therapy. “The Odyssey from Hope to Practice”, Santorini, Greece, 30 September – 3 October 2018

2018.The polymorphism rs6918289 located in the downstream region of the TREM2 gene is associated with TNF-α levels and IMT-F

The polymorphism rs6918289 located in the downstream region of the TREM2 gene is associated with TNF-α levels and IMT-F - 2018

2019.Peripheral blood mononuclear cells extracts VEGFprotein levels and VEGF mRNA- Associations with inflammatory molecules in a healthy population

Peripheral blood mononuclear cells extracts VEGF protein levels and VEGF mRNA: Associations with inflammatory molecules in a healthy population - 2019

2020.Epigenome-wide association study in healthy individuals identifies significant associations with DNA methylation and PBMC extract VEGF-A concentration

Epigenome-wide association study in healthy individuals identifies significant associations with DNA methylation and PBMC extract VEGF-A concentration - 2020

2021.A genetic determinant of VEGF-A levels is associated with telomere attrition

A genetic determinant of VEGF-A levels is associated with telomere attrition - 2021

2021.Epigenome-wide association study detects a novel loci associated with central obesity in healthy subjects

Epigenome‑wide association study detects a novel loci associated with central obesity in healthy subjects - 2021

2021.Nutrigenetic Interactions Might Modulate the Antioxidant and AntiInflammatory Status in MastihaSupplemented Patients With NAFLD

Nutrigenetic Interactions Might Modulate the Antioxidant and Anti-inflammatory Status in Mastiha-Supplemented Patients With NAFLD - 2021

2022.Association of Dietary Patterns with MRI Markers of Hepatic Inflammation and Fibrosis in the MAST4HEALTH Study

Association of Dietary Patterns with MRI Markers of Hepatic Inflammation and Fibrosis in the MAST4HEALTH Study - 2022

2022.Epigenome-Wide Association Study (EWAS) of Blood Lipids in Healthy Population from STANISLAS Family Study (SFS)

Epigenome-Wide Association Study (EWAS) of Blood Lipids in Healthy Population from STANISLAS Family Study (SFS) - 2022

Myocardial Infarction

2018.diagnostic-performance-of-a-combination-biomarker-algorithm-for-ruleout-of-acute-myocardial-infarction-at-time-of-presentation-to-2155-9880-1000600

Diagnostic Performance of a Combination Biomarker Algorithm for Rule- Out of Acute Myocardial Infarction at Time of Presentation to the Emergency Department, Using Heart-Type Fatty Acid-Binding Protein and High-Sensitivity Troponin T tests - 2018

2019.AnAlgorithm Based on Combining hs-cTnT and H-FABP for Ruling Out Acute Myocardial Infarction

An Algorithm Based on Combining hs-cTnT and H-FABP for Ruling Out Acute Myocardial Infarction - 2019

NASH / NAFLD

2022.Non-alcoholic fatty liver disease—A pilot study investigating early inflammatory and fibrotic biomarkers of NAFLD with alcoholic liver disease

Non-alcoholic fatty liver disease—A pilot study investigating early inflammatory and fibrotic biomarkers of NAFLD with alcoholic liver disease - 2022

Polypharmacy

2019.THE INTENSITY AND IMPACT OF CHRONIC PAIN, A STORY OF DIFFICULTY SLEEPING AND POSTTRAUMATIC STRESS DISORDER

A review of the prescribing culture of anti-depressants across government districts in Northern Ireland - 2023

Post-Traumatic Stress Disorder

2019.THE INTENSITY AND IMPACT OF CHRONIC PAIN, A STORY OF DIFFICULTY SLEEPING AND POSTTRAUMATIC STRESS DISORDER

The Intensity and Impact of Chronic Pain, a Story of Difficulty Sleeping and Post-Traumatic Stress Disorder - 2019

2020.Sleep, a Governor of Morbidity in PTSD-A Systematic Review of Biological Markers in PTSDRelated Sleep Disturbances

Sleep, a Governor of Morbidity in PTSD: A Systematic Review of Biological Markers in PTSD-Related Sleep Disturbances - 2020

2021.Post-traumatic stress disorder- A biopsychosocial case-control study investigating peripheral blood protein biomarkers

Post-traumatic stress disorder: A biopsychosocial case-control study investigating peripheral blood protein biomarkers - 2021

2022.ABSTRACT.improving-sleep-in-a-population-at-high-risk-of-trauma-a-pilot-study-examining-self-reported-sleep-psychological-symptomology-and-actigraphy-measured-night-t

Improving sleep in a population at high risk of trauma: A pilot study examining self-reported sleep, psychological symptomology and actigraphy measured night-time sleep - 2022

2022.Post-traumatic stress disorder; identifying potential differences in participant response to CAPS-5 life events checklist questionnaire based on gender

Post-Traumatic Stress Disorder: Identifying Potential Differences in Participant Response to CAPS-5 Life Events Checklist Questionnaire Based on Gender - 2022

2023.Sleep Disturbances and Chronic Pain as Potential Indicators for Therapeutic Intervention in Subjects with Post-Traumatic Stress Disorder

Sleep Disturbances and Chronic Pain as Potential Indicators for Therapeutic Intervention in Subjects with Post-Traumatic Stress Disorder - 2023

2023. REVIEW. Post-Traumatic Stress Disorder- Sleep Disturbances and Biomarkers

Post-Traumatic Stress Disorder: Sleep Disturbances and Biomarkers - Review - 2023

Pre-eclampsia

2024.Feto-maternal indicators of cardiac dysfunction as a justification for the cardiac origins for pre-eclampsia

Feto-maternal indicators of cardiac dysfunction as a justification for the cardiac origins for pre-eclampsia - 2024

Prostate Cancer

2019.ABSTRACT.McNAlly_et_al_diagnostic_classifiers_for_stratifying_patients_at_risk_of_prostate_cancer

Diagnostic classifiers for stratifying patients at risk of prostate cancer - 2019

2020.Biomarkers That Differentiate Benign Prostatic Hyperplasia from Prostate Cancer-A Literature Review

Biomarkers That Differentiate Benign Prostatic Hyperplasia from Prostate Cancer: A Literature Review - 2020

2022.A Novel Combination of Serum Markers in a Multivariate Model to Help Triage Patients Into “Low-” and “High-Risk” Categories for Prostate Cancer

A Novel Combination of Serum Markers in a Multivariate Model to Help Triage Patients Into “Low-” and “High-Risk” Categories for Prostate Cancer - 2022

Oncology

Randox & Transgene SS

Design and selection of anti-PD-L1 single-domain antibody and tumor necrosis factor superfamily ligands for an optimal vectorization in an oncolytic virus- 2023

Biosciences Bioreagents

Rapid Stratification of ARDs Flyer

APOE4 Flyer

Your Next Chosen Partner

Randox Bioreagents- Overview

Drug Induced Kidney Injury panel

Randox Bioreagents Recombinant Proteins

Biochip Overview

Randox Multiplex Stroke Biochip

Biosciences Overview Video

Randox Bioreagents- Polyclonal Antibodies

Randox Bioreagents- Monoclonal Antibodies

Randox Coronavirus Biochip Video

STI Campaign Video

Acute Kidney Injury


Request a meeting
×
Make an Enquiry - RX series
×
Make an Enquiry - Reagents
×
Kit Insert Request - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Kit Insert Request - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Reagents
×
Make an Enquiry - Quality Control
×
Make an Enquiry - RIQAS
×
Make an Enquiry - RIQAS
×
Make an Enquiry - Quality Control
×
Make an Enquiry
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Biochip
  • This field is for validation purposes and should be left unchanged.
×
Make an Enquiry - Molecular
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
  • This field is for validation purposes and should be left unchanged.
×
Make an Enquiry - Future Diagnostics
×
Make an Enquiry - RX series (Product)
×
Make an Enquiry - Quality Control
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - RIQAS
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Por favor, introduzca sus datos para ver nuestro último seminario
×
Wyślij zapytanie
  • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje Polityki Prywatności.
×
Wyślij zapytanie
  • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności.
×
Wyślij zapytanie
  • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności.
×
Wyślij zapytanie
    Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności .
×
귀하의 문의 사항 제출
    Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
귀하의 문의 사항 제출
×
귀하의 문의 사항 제출
×
귀하의 문의 사항 제출
×
Downloads
×
Contact

<p>

    Randox Clinical Chemistry Products Join the Randox Laboratories Mailing List * I would like to receive emails with new product releases and updates from Randox Laboratories, market trends, and more. I do not want to receive email marketing from Randox. Signing up to our mailing list is quick and easy. We do not want to send you any spam or junk emails, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promises never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
</p>

×
Enquire Now - Coronavirus Testing
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details safe and secure. Read more in our Privacy Policy.
×